Loading...
•
Sep 30, 2020
Repligen Q3 2020 Earnings Report
Reported record quarterly revenue with strong margin expansion.
Key Takeaways
Repligen reported a strong third quarter in 2020, achieving a record quarterly revenue of $94.1 million, driven by a 35% year-over-year growth and a 31% organic growth. COVID programs accounted for approximately 14% of revenue during the quarter, contributing to approximately 55% of revenue growth. The company also updated its full-year 2020 financial guidance, raising revenue expectations to $348-$352 million.
Repligen reported record quarterly revenue of $94.1 million, with a 35% year-over-year increase and 31% organic growth.
Gross margin (GAAP) was 57.9%, an increase of 3.1 points, and adjusted gross margin (non-GAAP) was 58.0%, an increase of 1.9 points compared to third quarter of 2019.
Operating margin (GAAP) was 22.3%, an increase of 10.8 points, and adjusted operating margin (non-GAAP) was 28.6%, an increase of 6.8 points compared to the third quarter of 2019.
The company raised revenue guidance to $348-$352 million and overall revenue growth to 29%-30% for full year 2020.
Repligen
Repligen
Forward Guidance
Repligen updated its financial guidance for the fiscal year 2020, projecting total revenue in the range of $348-$352 million and adjusted fully diluted EPS in the range of $1.41-$1.45.
Positive Outlook
- Total revenue is projected to be in the range of $348-$352 million, an increase from our previous guidance of $332-$340 million.
- Overall revenue growth of 29%-30%, with organic revenue growth in the range of 23%-24%.
- Gross margin is expected to be in the range of 57.5%-58.0% on both a GAAP and non-GAAP basis, compared to our previous guidance of 56.5%-57%.
- Income from operations is expected to be in the range of $66-$68 million on a GAAP basis, an increase from our previous guidance of $59-$62 million.
- Adjusted income from operations (non-GAAP) is expected to be in the range of $91-$93 million, an increase from our previous guidance of $81-$84 million.
Challenges Ahead
- The guidance does not include the impact of our proposed acquisition of ARTeSYN Biosolutions, which is expected to close during the fourth quarter of 2020.
- The guidance also excludes the impact of potential additional acquisitions and future fluctuations in foreign currency exchange rates.
- $9.2 million estimated acquisition and integration expenses.
- Expected inventory step-up charges of $0.2 million related to the acquisitions of Engineered Molding Technology and Non-Metallic Solutions.
- $15.8 million estimated intangible amortization expense.